FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892531430> ?p ?o ?g. }

• W2892531430 endingPage "526" @default.
• W2892531430 startingPage "519" @default.
• W2892531430 abstract "Background: There are few data comparing patient-reported outcomes (PROs) in randomized trials of initial antiretroviral therapy. We present results from a substudy of the NEAT001/ANRS143 trial. Methods: The randomized trial compared first-line DRV/r 800/100 mg once daily plus RAL 400 mg twice daily and DRV/r plus TDF/FTC 245/200 mg once daily. Changes in PROs were assessed with 3 questionnaires: EuroQoL 5 domains (EQ-5D), Center for Epidemiologic Studies Depression (CES-D) scale, and HIV Treatment Satisfaction Questionnaire. Major depressive disorder (MDD) was defined as CES-D ≥ 16. General estimating equations were used to model change over 96 weeks in PROs from baseline. Results: Of the 805 participants, 797 (99%) contributed to the substudy. Baseline PRO data were similar for the 2 randomized groups. Health status improved over time with a mean increase in EQ-5D visual analogue scale (VAS) of 8.0 by W96 [95% confidence interval (CI): 6.5 to 9.4; P < 0.001], and no statistically significant differences between groups (difference of 0.3 on VAS score (95% CI: −1.7 to 2.3); P = 0.7, global P value ≥0.05 for all domains over follow-up). There was no significant difference between groups on CES-D [difference of −0.1 (95% CI: −1.3 to 1.1); P = 0.9], or MDD during follow-up, adjusted for baseline MDD (odds ratio = 0.98, 95% CI: 0.82 to 1.18; P = 0.9). RAL + DRV/r group had lower level of convenience ( P = 0.03) and fitted less well into patients' lifestyle ( P = 0.007) than the TDF/FTC + DRV/r regimen, and was associated with lower treatment satisfaction [median score: 53 RAL + DRV/r vs 55 TDF/FTC + DRV/r ( P = 0.001)]. Conclusion: PROs improved after starting antiretroviral therapy, with no statistically significant difference between groups. The lower satisfaction with RAL + DRV/r may be explained by twice-daily administration." @default.
• W2892531430 created "2018-10-05" @default.
• W2892531430 creator A5019198664 @default.
• W2892531430 creator A5026739355 @default.
• W2892531430 creator A5027457337 @default.
• W2892531430 creator A5040670283 @default.
• W2892531430 creator A5043988249 @default.
• W2892531430 creator A5046238828 @default.
• W2892531430 creator A5046412532 @default.
• W2892531430 creator A5048050447 @default.
• W2892531430 creator A5056512475 @default.
• W2892531430 creator A5058642476 @default.
• W2892531430 creator A5068809984 @default.
• W2892531430 creator A5072373359 @default.
• W2892531430 creator A5078602822 @default.
• W2892531430 creator A5078642431 @default.
• W2892531430 creator A5085919150 @default.
• W2892531430 creator A5086736643 @default.
• W2892531430 date "2018-12-01" @default.
• W2892531430 modified "2023-10-14" @default.
• W2892531430 title "Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir" @default.
• W2892531430 cites W1966537317 @default.
• W2892531430 cites W1976747571 @default.
• W2892531430 cites W2000868000 @default.
• W2892531430 cites W2009615575 @default.
• W2892531430 cites W2027863312 @default.
• W2892531430 cites W2041726169 @default.
• W2892531430 cites W2055734526 @default.
• W2892531430 cites W2061410297 @default.
• W2892531430 cites W2085139072 @default.
• W2892531430 cites W2099658521 @default.
• W2892531430 cites W2121737909 @default.
• W2892531430 cites W2124892175 @default.
• W2892531430 cites W2132508575 @default.
• W2892531430 cites W2140316958 @default.
• W2892531430 cites W2153836018 @default.
• W2892531430 cites W2169236274 @default.
• W2892531430 cites W2238552371 @default.
• W2892531430 cites W2330407981 @default.
• W2892531430 cites W2479965455 @default.
• W2892531430 cites W2529566545 @default.
• W2892531430 cites W2580175227 @default.
• W2892531430 cites W4294185218 @default.
• W2892531430 doi "https://doi.org/10.1097/qai.0000000000001844" @default.
• W2892531430 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6420069" @default.
• W2892531430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30234665" @default.
• W2892531430 hasPublicationYear "2018" @default.
• W2892531430 type Work @default.
• W2892531430 sameAs 2892531430 @default.
• W2892531430 citedByCount "5" @default.
• W2892531430 countsByYear W28925314302019 @default.
• W2892531430 countsByYear W28925314302020 @default.
• W2892531430 countsByYear W28925314302021 @default.
• W2892531430 countsByYear W28925314302023 @default.
• W2892531430 crossrefType "journal-article" @default.
• W2892531430 hasAuthorship W2892531430A5019198664 @default.
• W2892531430 hasAuthorship W2892531430A5026739355 @default.
• W2892531430 hasAuthorship W2892531430A5027457337 @default.
• W2892531430 hasAuthorship W2892531430A5040670283 @default.
• W2892531430 hasAuthorship W2892531430A5043988249 @default.
• W2892531430 hasAuthorship W2892531430A5046238828 @default.
• W2892531430 hasAuthorship W2892531430A5046412532 @default.
• W2892531430 hasAuthorship W2892531430A5048050447 @default.
• W2892531430 hasAuthorship W2892531430A5056512475 @default.
• W2892531430 hasAuthorship W2892531430A5058642476 @default.
• W2892531430 hasAuthorship W2892531430A5068809984 @default.
• W2892531430 hasAuthorship W2892531430A5072373359 @default.
• W2892531430 hasAuthorship W2892531430A5078602822 @default.
• W2892531430 hasAuthorship W2892531430A5078642431 @default.
• W2892531430 hasAuthorship W2892531430A5085919150 @default.
• W2892531430 hasAuthorship W2892531430A5086736643 @default.
• W2892531430 hasBestOaLocation W28925314301 @default.
• W2892531430 hasConcept C126322002 @default.
• W2892531430 hasConcept C14184104 @default.
• W2892531430 hasConcept C142462285 @default.
• W2892531430 hasConcept C156957248 @default.
• W2892531430 hasConcept C168563851 @default.
• W2892531430 hasConcept C1862650 @default.
• W2892531430 hasConcept C2778464720 @default.
• W2892531430 hasConcept C2779134260 @default.
• W2892531430 hasConcept C2779144063 @default.
• W2892531430 hasConcept C2779182219 @default.
• W2892531430 hasConcept C2779298103 @default.
• W2892531430 hasConcept C2779465607 @default.
• W2892531430 hasConcept C2779778239 @default.
• W2892531430 hasConcept C2780051608 @default.
• W2892531430 hasConcept C2780404665 @default.
• W2892531430 hasConcept C2993143319 @default.
• W2892531430 hasConcept C3013748606 @default.
• W2892531430 hasConcept C3019006561 @default.
• W2892531430 hasConcept C44249647 @default.
• W2892531430 hasConcept C512399662 @default.
• W2892531430 hasConcept C71924100 @default.
• W2892531430 hasConceptScore W2892531430C126322002 @default.
• W2892531430 hasConceptScore W2892531430C14184104 @default.
• W2892531430 hasConceptScore W2892531430C142462285 @default.
• W2892531430 hasConceptScore W2892531430C156957248 @default.
• W2892531430 hasConceptScore W2892531430C168563851 @default.

• next